The 2014 annual meeting of the American Society of He­ma­tol­ogy (ASH) starts tomorrow, De­cem­ber 5, in San Francisco, and will con­tinue until next Tuesday.

The ASH annual meeting is one of sev­er­al large med­i­cal conferences where myeloma-related re­search findings are pre­sented each year.  However, from a mul­ti­ple myeloma perspective, the ASH meeting is generally the most im­por­tant of the meetings.

At this year’s meeting, for example, some 500 myeloma-presentations are scheduled to take place.  The pre­sen­ta­tions will summarize cur­rent re­search on a wide range of topics, in­clud­ing the biology of the dis­ease …

• This Phase I trial will test the safety and tolerability of lirilumab (BMS-986015) in combination with elotuzumab (BMS-901608) in patients with multiple myeloma
• This new Phase I initiated by Bristol-Myers Squibb is the first combination trial of lirilumab in a hematological tumor type

Marseille, France (Press Release) - Innate Pharma SA (the "company" -  euronext paris:FR0010331421 - IPH), the innate immunity com­pany devel­op­ing first-in-class thera­peutic anti­bodies for cancer and in­flam­ma­tory dis­eases, to­day an­nounced that a new Phase I com­bi­na­tion trial with lirilumab, a …

The pharma­ceu­tical com­pa­nies Bristol-Myers Squibb and AbbVie an­nounced this morn­ing that the U.S. Food and Drug Admin­istra­tion has granted break­through ther­apy desig­na­tion to the inves­ti­ga­tional drug elo­tuz­u­mab.

Specifically, the Food and Drug Admin­istra­tion (FDA) granted break­through ther­a­py desig­na­tion to elotuzumab in com­bi­na­tion with Revlimid (lena­lido­mide) and dexamethasone (Decadron) for mul­ti­ple myeloma patients who have re­ceived one or more prior ther­a­pies.

The break­­through ther­apy desig­na­tion is a new desig­na­tion that was signed into law in 2012. It is de­signed to ac­cel­er­ate the de­vel­op­ment and review process for drugs in­tended …

Designation granted for inves­ti­ga­tional agent elotuzumab in com­bi­na­tion with lena­lido­mide and dexa­meth­a­sone for treat­ment of mul­ti­ple myeloma in patients who have re­ceived one or more prior ther­a­pies

Princeton, NJ and North Chicago, IL (Press Release) – Bristol-Myers Squibb Com­pany (NYSE:BMY) and AbbVie (NYSE:ABBV) to­day an­nounced that the U.S. Food and Drug Admin­istra­tion (FDA) has granted elotuzumab, an inves­ti­ga­tional humanized mono­clonal anti­body, Break­through Therapy Desig­na­tion for use in com­bi­na­tion with lena­lido­mide and dexa­meth­a­sone for the treat­ment of mul­ti­ple myeloma in patients who have re­ceived one or more prior ther­a­pies. The desig­na­tion is based on findings from a ran­dom­ized Phase 2, open-label study that eval­u­ated two dose levels of elotuzumab in com­bi­na­tion with lena­lido­mide and low-dose dexa­meth­a­sone in pre­vi­ously-treated …

• Median progression-free survival (PFS) of 33 months reached after longer-term follow up in patients treated with elotuzumab 10 mg/kg plus lenalidomide and low-dose dexamethasone
• Longer-term safety profile of the combination consistent with previously reported results
• Results Presented at 18th Annual Congress of the European Hematology Association
• Two Phase 3 studies of elotuzumab at 10 mg/kg dose ongoing in patients with previously-treated and newly-diagnosed multiple myeloma

Princeton, NJ and North Chicago, IL (Press Release) – Bristol-Myers Squibb Com­pany (NYSE: BMY) and AbbVie (NYSE: ABBV) to­day an­nounced up­dated ef­fi­cacy and safety data from a small, ran­dom­ized Phase 2, open-label study in patients with pre­vi­ously-treated mul­ti­ple myeloma that eval­u­ated two doses of the inves­ti­ga­tional mono­clonal anti­body elotuzumab (10 mg/kg and 20 mg/kg) in com­bi­na­tion with lena­lido­mide and low-dose dexa­meth­a­sone. In the 10 mg/kg arm (N=36), which is the dose used in the on­go­ing Phase 3 trials, median pro­gres­sion-free sur­vival (PFS), or the time without dis­ease pro­gres­sion, …

This year’s meeting of the American Society of Clinical Oncology (ASCO) was held May 31 through June 4 in Chicago.

During the meeting, The Beacon pub­lished daily up­dates that provided over­views of the im­por­tant mul­ti­ple myeloma findings pre­sented during the meeting.

Now that the meeting has concluded, the focus shifts to the bigger picture: What were the key findings of the meeting? Were there re­­sults with im­medi­ate im­pli­ca­­tions for the treat­ment of mul­ti­ple myeloma?  Did the re­search at the meeting rep­re­sent a major step for­ward for myeloma patients, or …

This year’s American Society of Clinical Oncology (ASCO), which was held in Chicago, began on Friday and concluded on Tuesday.

Monday was the busiest day at the meeting with regard to myeloma re­search.  It featured a session of oral pre­sen­ta­tions in the morn­ing and a poster session in the afternoon.

This up­date summarizes the myeloma-related stud­ies pre­sented during the afternoon poster session, which was the final myeloma-related session of the meeting. An earlier article covered the findings from the oral pre­sen­ta­tions that were given in the morn­ing.

Most of the key …